ID

28389

Descrição

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; Eligibility ODM derived from: https://clinicaltrials.gov/show/NCT00512083

Link

https://clinicaltrials.gov/show/NCT00512083

Palavras-chave

  1. 10/01/2018 10/01/2018 - Julian Varghese
  2. 10/01/2018 10/01/2018 - Stefan Hegselmann
Titular dos direitos

Mueller

Transferido a

10 de janeiro de 2018

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Leukemia, Myeloid NCT00512083

Eligibility Leukemia, Myeloid NCT00512083

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
primary refractory or relapsed aml
Descrição

ID.1

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0278780
confirmed diagnosis of aml (de novo or secondary) as defined by who classification (vardiman 2002)
Descrição

ID.2

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0011900
aged at least 18 years
Descrição

ID.3

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
Does the subject have an Eastem Cooperative Oncology Group (ECOG) Performance Status (PS) greater than 2?
Descrição

ECOG performance

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
initial diagnosis of acute promyelocytic leukemia as defined by french-american-british criteria (bennett 1976)
Descrição

ID.4

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0023487
patient in blast crisis stage of chronic myeloid leukemia
Descrição

ID.5

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0919644
received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
Descrição

ID.6

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0010711
interval of <6 months between first onset of last complete remission and current relapse
Descrição

ID.7

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0677874
UMLS CUI [1,2]
C0035020
those with primary refractory leukemia who have received more than three previous induction cycles
Descrição

ID.8

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0857127
UMLS CUI [1,2]
C0392920
relapsed patients who have received more than three previous treatment regimens
Descrição

ID.9

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0392920

Similar models

Eligibility Leukemia, Myeloid NCT00512083

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
primary refractory or relapsed aml
boolean
C0278780 (UMLS CUI [1])
ID.2
Item
confirmed diagnosis of aml (de novo or secondary) as defined by who classification (vardiman 2002)
boolean
C0023467 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
ID.3
Item
aged at least 18 years
boolean
C0001779 (UMLS CUI [1])
ECOG performance
Item
Does the subject have an Eastem Cooperative Oncology Group (ECOG) Performance Status (PS) greater than 2?
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
ID.4
Item
initial diagnosis of acute promyelocytic leukemia as defined by french-american-british criteria (bennett 1976)
boolean
C0023487 (UMLS CUI [1])
ID.5
Item
patient in blast crisis stage of chronic myeloid leukemia
boolean
C0919644 (UMLS CUI [1])
ID.6
Item
received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
boolean
C0010711 (UMLS CUI [1])
ID.7
Item
interval of <6 months between first onset of last complete remission and current relapse
boolean
C0677874 (UMLS CUI [1,1])
C0035020 (UMLS CUI [1,2])
ID.8
Item
those with primary refractory leukemia who have received more than three previous induction cycles
boolean
C0857127 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
ID.9
Item
relapsed patients who have received more than three previous treatment regimens
boolean
C0392920 (UMLS CUI [1])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial